arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Entrada Therapeutics, Inc.

TRDA

$6.86 0.00 (0.00%) at close

7 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Entrada Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $283.8M

Dividend Yield —

Revenue Growth -87.9% ↘

Op. Margin None

ROIC -40.7% ↘

FCF / Share $-3.13 ↘

Trailing P/E —

Price / Book 0.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$25.42M

↓ -87.9% —

Net Income Profit after all expenses

$-143.75M

↓ -319.0% —

Operating Margin Operating profit as % of sales

22.3%

↑ +1010.0% —

FCF / Share Free cash flow per share

$-3.13

↓ -161.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	-87.9% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1199%)	63.4% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+692%)	—	—	—	—	—
EPS Growth YoY (%)	N/M	N/M	93.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	63.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	66.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	N/M	N/M	92.9% Excellent ↑ Excellent Improving Year-over-year change in net income	-84.9% Weak Weak Year-over-year change in net income	-92.9% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-161.3% Weak Weak Year-over-year change in free cash flow	N/M	N/M	65.1% Excellent Excellent Year-over-year change in free cash flow	64.9% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	—	22.3% Good Good Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+49%)	-2.5% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-116%)	—	—	—	—
Profit Margin (%) (%)	—	31.1% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+159%)	-5.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-143%)	—	—	—	—
FCF Margin (%) (%)	—	-21.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	104.0% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.90x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	-0.68x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-20.07x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.02x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	1.08x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-40.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	8.7% Fair ↑ Fair Improving Return earned on debt + equity capital invested Optimal: > 10%	-1.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-36.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	50.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-41.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	8.9% Fair ↑ Fair Improving Operating profit relative to total assets Optimal: > 10%	-0.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-38.6% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-16.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-61.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-47.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-413%)	15.3% Good ↑ Good Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: At sector avg	-2.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-118%)	-44.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-397%)	-17.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-214%)	63.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+326%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-90.39M	$-101.21M	$-67.60M	$-45.16M	$-291.06M	$-39.05M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.61	$5.65	$3.90	—	—	—	—
Basic EPS, GAAP (USD)	$-3.47	$1.76	$-0.20	$-3.02	$-8.16	$-24.00	—
Free Cash Flow per Share (USD)	$-3.13	$-1.20	$4.06	$-3.09	$-8.85	$-25.23	—
Book Value per Share (USD)	$8.00	$11.41	$7.25	$6.77	$9.57	$-33.35	—
Tangible Book Value per Share (USD)	$8.00	$11.41	$7.25	$6.77	$9.57	$-33.35	—
Basic Weighted Avg Shares (shares)	41.37M	37.31M	33.05M	31.29M	6.27M	1.11M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$281.80M	$400.56M	$210.97M	$187.90M	$291.98M	$36.59M	—
Total Equity (USD)	$306.13M	$428.68M	$242.36M	$212.55M	$298.72M	$-41.49M	$-15.52M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$25.42M	$210.78M	$129.01M	—	—	—	—
Depreciation Expense (USD)	$4.10M	$3.77M	$2.84M	$1.90M	$1.12M	$326.00K	—
Net Income, GAAP (USD)	$-143.75M	$65.63M	$-6.68M	$-94.62M	$-51.16M	$-26.52M	—
Operating Cash Flow (USD)	$-128.51M	$-41.56M	$139.80M	$-93.79M	$-50.86M	$-25.57M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Entrada Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare TRDA with peers